MAPT and Alzheimer disease: Others have ascribed the detrimental functions of TREM2 to sTREM2, which in early symptomatic phases was shown to be elevated in the CSF and plasma of AD subjects, in association with higher phospho-tau levels (Heslegrave et al., 2016; Piccio L et al., 2016).